Skip to main content

Table 4 Changes of echocardiographic parameters after 3 months of placebo treatment

From: Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)

 

Mean ± standard deviation

95% CI (mean)

median and interquartile ranges

Parameter

N

lower limit

upper limit

Echocardiography

 right atrial area [cm2]

5

−0.4 ± 2.9

−4.1

3.2

1 [−3.2; 2]

 right ventricular area [cm2]

5

2.0 ± 6.4

−6.0

9.8

0 [−5.3; 10]

 TAPSE [mm]

5

0.5 ± 3.3

−3.6

4.5

0 [−2.6; 6]

 RV thickness [mm]

4

1.0 ± 0.8

−0.3

2.3

1.0 [0.5; 1.5]

 TRV [cm/sec]

4

0.1 ± 0.2

−0.3

0.4

0.1 [−0.1; 0.3]

 IVC diameter [mm]

5

−0.4 ± 2.7

−3.8

2.9

0 [0; 0.8]

 LV-EI

5

−0.1 ± 0.1

−0.2

0.03

−0.1 [− 0.2; 0]

 PA diameter [mm]

4

−0.25 ± 1.3

−2.3

1.8

0 [−1.0; 0.5]

  1. TAPSE = tricuspid annular plane systolic excursion; FAC = Fractional area change; RV = right ventricular
  2. TRV tricuspid regurgitation velocity, IVC inferior vena cava, LV-EI left ventricular eccentricity index
  3. PA pulmonary artery